Mark Hodgson is a Partner in the IP and Technology
Dispute Resolution Group at Field Fisher Waterhouse which he
joined from Howrey's in 2011.
Mark specialises in advising pharmaceutical,
medical device and biotechnology companies on intellectual
property, regulatory, product liability and parallel importation
matters. He has represented his clients successfully before the UK
courts and has managed litigation on a multi-jurisdictional basis.
His experience includes all forms of licensing including compulsory
licensing as well as in advising clients on the intellectual
property aspects of acquisitions.
He is recognised as a 'leading individual' in
his field by both Chambers and Legal 500 as well
as one of 'the top ten patent lawyers worldwide' by Global Counsel.
He was one of The Lawyer magazine's 'Hot 100' lawyers in 2008. He
led the team awarded 'TMT team of the year' in the Chambers Awards
of 2009.
Mark has written numerous articles for legal
and pharmaceutical journals and lectures extensively on matters
such as parallel importation, enforcement, medicinal law
regulations and strategic alliances.
Representative Matters
- Lilly ICOS v Pfizer (2005). A high profile patent
revocation action concerning the patent for the use of
phosphodiesterase inhibitors (including VIAGRA) to treat impotence.
Successful at first instance and on appeal.
- Angiotech v Conor Medsystems (2007). Relating to the
patent for the drug-eluting stent (TAXUS). The case concerns the
appropriate test for determining lack of inventive step and
Angiotech (Howrey's client) were successful before the House of
Lords in June 2008. Leading IP case of the year.
- Eli Lilly v Human Genome Sciences. Successfully
represented Eli Lilly in July 2008 before the Patents Court in the
leading UK authority on the law of industrial applicability. Also
successfully defended the appeal before the Court of Appeal in
2009. The Supreme Court will hear the case (the first ever IP case
heard by the court) in July 2011.
- Eli Lilly v Dr. Reddy. Successfully represented Eli
Lilly in October 2008 against revocation action brought by generic
companies aimed at invalidating Lilly's primary patent for
olanzapine (ZYPREXA).